CryoPort, Inc. (CYRX)

NASDAQIndustrialsIntegrated Freight & LogisticsSnapshot 2026-10-23

$17.98+0.84%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge CryoPort, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	50.04M
EPS	—	-0.168
Annual ending 2026-12-31
Revenue	—	195.47M
EPS	—	-0.788
Annual ending 2027-12-31
Revenue	—	215.18M
EPS	—	-0.646

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross profit improves beyond $21.9 million quarterly	Gross profit is improving, rising from $21.3M to $21.9M recently.	Improving	Gross profit falls below $21.9 million in any quarter	Gross profit: $22.824M FY2026-Q2; GAAP. Published target: >= $21.9 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 202622,824,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 731df862-9e75-4652-9266-ae7b287838b5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Total gross margin remained stable at about 46.6% in 2026-Q2 versus 47.0% in 2025-Q2, with Life Sciences Services margin improving from 48.9% to 49.9%. Management's focus on margin expansion and operating efficiency shows limited progress but positive trajectory in services segment margins. Delivery assessment Oct 24, 2026
Cash from operations exceeds $3.7 million quarterly	Cash from operations increased from $0.9M to $3.7M, showing better cash flow.	Broken	Cash from operations falls below $3.7 million in any quarter	Cash from operations: $1.131M FY2026-Q2; GAAP. Published target: >= $3.7 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 20261,131,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash from operations improved from $0.9 million in 2025-Q4 to $3.7 million in 2026-Q1, and adjusted EBITDA turned positive to $0.4 million in 2026-Q2 from negative $0.9 million in 2025-Q2. Management is delivering progress on cash flow and profitability milestones, indicating a positive trajectory. Delivery assessment Oct 24, 2026
Full-year revenue reaches at least $192 million in 2026	A primary condition in CryoPort, Inc.'s published investment case. The stated target is >= $192 million.	Intact	Full-year revenue falls below $192 million in 2026	Revenue: $48.971M FY2026-Q2; GAAP. Published target: >= $192 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 202648,971,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 731df862-9e75-4652-9266-ae7b287838b5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $45.5 million in 2025-Q2 to $49.0 million in 2026-Q2, an 8% increase year-over-year. Management raised full-year 2026 revenue guidance from $190-$194 million to $192-$196 million, reflecting delivery on growth momentum and an upward trajectory. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.22B

$0.21B → $0.22B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$213,101,440	3 / 9
2026-07-25	Unavailable	$213,101,440	3 / 9
2026-07-26	Unavailable	$213,101,440	3 / 9
2026-07-27	Unavailable	$213,101,444	4 / 6
2026-07-28	Unavailable	$213,101,440	3 / 9
2026-07-29	Unavailable	$213,101,440	3 / 9
2026-07-30	Unavailable	$213,101,440	3 / 9
2026-07-31	Unavailable	$213,101,440	3 / 9
2026-08-01	Unavailable	$213,101,444	4 / 6
2026-08-02	Unavailable	$213,101,440	3 / 9
2026-08-03	Unavailable	$213,101,444	4 / 6
2026-08-04	Unavailable	$213,101,440	3 / 9
2026-08-05	Unavailable	$213,145,889	4 / 6
2026-08-06	Unavailable	$213,101,440	3 / 9
2026-08-07	Unavailable	$213,145,889	4 / 6
2026-08-08	Unavailable	$213,634,780	3 / 9
2026-08-09	Unavailable	$213,145,889	4 / 6
2026-08-10	Unavailable	$213,145,889	4 / 6
2026-08-11	Unavailable	$213,145,889	4 / 6
2026-08-12	Unavailable	$213,145,889	4 / 6
2026-08-13	Unavailable	$213,145,889	4 / 6
2026-08-14	Unavailable	$213,145,889	4 / 6
2026-08-15	Unavailable	$213,145,889	4 / 6
2026-08-16	Unavailable	$213,145,889	4 / 6
2026-08-17	Unavailable	$213,145,889	4 / 6
2026-08-18	Unavailable	$213,145,889	4 / 6
2026-08-19	Unavailable	$213,145,889	4 / 6
2026-08-20	Unavailable	$214,923,000	4 / 6
2026-08-21	Unavailable	$214,923,000	4 / 6
2026-08-22	Unavailable	$214,923,000	4 / 6
2026-08-23	Unavailable	$214,923,000	4 / 6
2026-08-24	Unavailable	$214,923,000	4 / 6
2026-08-25	Unavailable	$214,924,333	4 / 6
2026-08-26	Unavailable	$214,924,333	4 / 6
2026-08-27	Unavailable	$214,924,333	4 / 6
2026-08-28	Unavailable	$214,924,333	4 / 6
2026-08-29	Unavailable	$214,924,333	4 / 6
2026-08-30	Unavailable	$214,924,333	4 / 6
2026-08-31	Unavailable	$214,924,333	4 / 6
2026-09-01	Unavailable	$214,924,333	4 / 6
2026-09-02	Unavailable	$214,924,333	4 / 6
2026-09-03	Unavailable	$214,924,333	4 / 6
2026-09-04	Unavailable	$214,924,333	4 / 6
2026-09-05	Unavailable	$214,924,333	4 / 6
2026-09-06	Unavailable	$214,924,333	4 / 6
2026-09-07	Unavailable	$214,924,333	4 / 6
2026-09-08	Unavailable	$214,924,333	4 / 6
2026-09-09	Unavailable	$214,924,333	4 / 6
2026-09-10	Unavailable	$214,924,333	4 / 6
2026-09-11	Unavailable	$214,924,333	4 / 6
2026-09-12	Unavailable	$214,924,333	4 / 6
2026-09-13	Unavailable	$214,924,333	4 / 6
2026-09-14	Unavailable	$214,924,333	4 / 6
2026-09-15	Unavailable	$214,924,333	4 / 6
2026-09-16	Unavailable	$214,924,333	4 / 6
2026-09-17	Unavailable	$214,921,416	4 / 6
2026-09-18	Unavailable	$214,921,416	4 / 6
2026-09-19	Unavailable	$214,921,416	4 / 6
2026-09-20	Unavailable	$214,921,416	4 / 6
2026-09-21	Unavailable	$214,921,416	4 / 6
2026-09-22	Unavailable	$214,921,416	4 / 6
2026-09-23	Unavailable	$214,921,416	4 / 6
2026-09-24	Unavailable	$214,921,416	4 / 6
2026-09-25	Unavailable	$214,921,416	4 / 6
2026-09-26	Unavailable	$214,921,416	4 / 6
2026-09-27	Unavailable	$214,921,416	4 / 6
2026-09-28	Unavailable	$214,921,416	4 / 6
2026-09-29	Unavailable	$214,921,416	4 / 6
2026-09-30	Unavailable	$214,921,416	4 / 6
2026-10-01	Unavailable	$214,921,416	4 / 6
2026-10-02	Unavailable	$214,921,416	4 / 6
2026-10-03	Unavailable	$214,921,416	4 / 6
2026-10-04	Unavailable	$214,921,416	4 / 6
2026-10-05	Unavailable	$214,921,416	4 / 6
2026-10-06	Unavailable	$214,921,416	4 / 6
2026-10-07	Unavailable	$214,921,416	4 / 6
2026-10-08	Unavailable	$214,921,416	4 / 6
2026-10-09	Unavailable	$214,921,416	4 / 6
2026-10-10	Unavailable	$214,921,416	4 / 6
2026-10-11	Unavailable	$214,921,416	4 / 6
2026-10-12	Unavailable	$214,921,416	4 / 6
2026-10-13	Unavailable	$214,921,416	4 / 6
2026-10-14	Unavailable	$215,163,638	4 / 6
2026-10-15	Unavailable	$215,163,638	4 / 6
2026-10-16	Unavailable	$215,163,638	4 / 6
2026-10-17	Unavailable	$215,163,638	4 / 6
2026-10-18	Unavailable	$215,163,638	4 / 6
2026-10-19	Unavailable	$215,163,638	4 / 6
2026-10-20	Unavailable	$215,163,638	4 / 6
2026-10-21	Unavailable	$215,163,638	4 / 6
2026-10-22	Unavailable	$215,163,638	4 / 6
2026-10-23	Unavailable	$215,163,638	4 / 6
2026-10-24	Unavailable	$215,183,972	4 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	1
2026-06-01	8	1
2026-07-01	8	1
2026-08-01	8	1
2026-09-01	8	1
2026-10-01	8	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Robert W. BairdOct 13

$26.00New observation · no comparable prior

BTIGOct 13 · prior Jul 24

$25.00 → $26.00+4.0%

GuggenheimOct 1 · prior Aug 7

$16.00 → $19.00+18.8%

$0$14.30$28.60

2 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross profit improves beyond $21.9 million quarterlyGross profit: $22.824M
Cash from operations exceeds $3.7 million quarterlyPublished status: Broken
Full-year revenue reaches at least $192 million in 2026Revenue: $48.971M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-31.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

CryoPort, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This investment represents a turnaround story with a medium confidence level. The company is currently loss-making but has shown some positive momentum in cash flow and revenue guidance, though recent financial performance has been weak.

What's priced into CryoPort, Inc.

The market seems to have priced in a low expectations gap, indicating that investors are not overly optimistic about immediate performance. Valuation appears cheap compared to peers, but there is a premium reflecting the optionality in its business model.

What the fundamentals likely do

Management is focused on increasing revenue guidance and improving margins, with some progress noted in cash flow. However, the overall financial performance remains weak, and the risk of missing future guidance is present.

What CryoPort, Inc. hinges on

The long-term thesis hinges on the ability of sector leaders like UPS and FDX to maintain positive earnings and guidance. Any cuts in guidance from CYRX could lead to significant negative sentiment.